Nephrotoxicity of cis-diamminedichloride platinum (CDDP) during remission-induction and maintenance chemotherapy of testicular carcinoma

Meijer, S; Mulder, Nh; Sleijfer, Dt; Dejong, Pe; Sluiter, Wj; Koops, H. Schraffordt; Vanderhem, Gk

doi:10.1007/bf00292867

Cited by 37 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in our present study, a significant increase in serum creatinine level was not observed (data not shown). Groth et al [8] and Meijer et al [9] reported that the scrum creatinine level was a less suitable parameter for monitoring renal side effects of cisplatin than C<> Therefore, renal function was evaluated by Co-in the present study. Our results demonstrated that neither the cumulative dose of cispla tin nor accumulated Pt in the kidney affected renal func tion, as far as Co-was utilized to assess renal function.…”

Section: Discussionmentioning

confidence: 99%

Platinum Accumulation in the Kidney and Changes in Creatinine Clearance following Chemotherapy with Cisplatin in Humans

Uozumi¹,

Ueda²,

Yasumasu³

et al. 1993

Urol Int

View full text Add to dashboard Cite

To evaluate the effects of repeated administration of cisplatin on kidney platinum (Pt) accumulation and renal function, Pt content in the kidney was determined in 31 autopsy cases and changes in creatinine clearance (Co) were retrospectively assessed in 26 of 31 autopsy cases. There was no significant correlation between the cumulative dose of cisplatin and Pt content in the kidney. However, the kidney Pt level was correlated with the dose of cisplatin injected within a 7-month period prior to the patient’s death. We suggest that the dose of cisplatin injected during a relatively short period before a patient’s death affects Pt content in the kidney. Neither the total dose of cisplatin nor the Pt content in the kidney was significantly correlated with the decrease in Co-following chemotherapy with cisplatin.

show abstract

Section: Discussionmentioning

confidence: 99%

Platinum Accumulation in the Kidney and Changes in Creatinine Clearance following Chemotherapy with Cisplatin in Humans

Uozumi¹,

Ueda²,

Yasumasu³

et al. 1993

Urol Int

View full text Add to dashboard Cite

show abstract

“…Some have reported cumulative and unpredictable nephrotoxicity (Goren et al, 1986) while others have related cumulative toxicity to renal cortical platinum concentrations (Stewart et al, 1985). Others have denied any cumulative toxicity (Meijer et al, 1982;Chiuten et al, 1983) (Daugaard et al, 1988), in the stable pretreatment or long post-treatment situation an excellent correlation between serum creatinine and GFR is seen (Daugaard et al, 1988) and indeed some have suggested that serum creatinine is the preferred measure of GFR (Payne, 1986). The rise in serum creatinine in this population is thus considered to be due to renal damage which is largely determined by the cummulative dose of cisplatin.…”

Section: Renal Functionmentioning

confidence: 99%

Long-term toxicity of chemotherapy for testicular cancer – the cost of cure

Stuart

Woodroffe²,

Grundy³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

Summary Twenty-seven patients cured of advanced testicular cancer by cisplatin-based chemotherapy have been assessed, a median of 30 months after start of treatment, for the long-term effects of such treatment on renal, endocrine, audiometric, reproductive and respiratory function. To control for the effects of orchidectomy on endocrine function a similar group of 11 patients cured by orchidectomy alone was also assessed. The extents of impairment in hearing and renal function were related to the total dose of cisplatin received, while the majority of patients had respiratory impairment which was, in part, related to the total dose of bleomycin. TSH was significantly higher in the chemotherapy group although serum free thyroxine and free T3 were normal in all. FSH was raised in 67% of the chemotherapy group and in 45% of the orchidectomy group while LH was raised in 75% and 45% respectively. Serum testosterone was normal in all. MethodsClinical notes were reviewed to obtain details of investigations at presentation and of chemotherapy received. Hepatic and renal function, serum TSH, free thyroxine and free T3, serum FSH, LH and testosterone, tumour markers (afetoprotein and P-human chorionic gonadotrophin) and full blood count were measured. Standard laboratory normal ranges were used and serum hormones were measured by specific immunometric methods.Pulmonary function assessment comprised measurement of vital capacity (VC), forced residual capacity (FRC), residual volume (RV), total lung capacity (TLC), forced expiratory capacity in one second (FEV,), peak expiratory flow rate (PFR), transfer factor coefficient (KCO), total lung transfer factor (TLCO), total alveolar volume (TAV) and effective alveolar volume (EAV). TLCO was measured by single breath-hold method with correction for haemoglobin concentration, EAV by single breath helium dilution and lung volumes by steady state helium dilution. Values other than TAV and EAV were expressed as standardised residuals (Miller & Pincock, 1988) with expected values determined from height and age by published regression equations (European Coal and Steel Community Recommendations, 1983

show abstract

“…The disadvantage of these methods is that they measure only GFR. Previous studies with cisplatin have shown a decrease in GFR and ERPF after treatment [18,19,21]. Also, an increase in FF has been observed, implying that ERPF decreases more than GFR [21].…”

Section: Discussionmentioning

confidence: 76%